![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 09, 2019 7:13:07 PM
Oh yeah, and then they have to formulate the different doses of CBD with the 2 doses of gum (I assume this because some people are very addicted to tobacco (chew constantly) and some less addicted. They need to be able to show they can formulate a precise amount of CBD with the different strengths of nicotine. Not easy but do-able. Once they do that, then they can propose a phase 1 study. Normally a phase 1 study is in healthy volunteers, but I suspect they will conduct it in chewers. Why? Because in non-tobacco users, nicotine gum will have adverse events related to nicotine. Regular users will be accustomed to that.
So in Q4, I suspect they create a real clinical development plan that will call for studying 25-40 tobacco users. They'll also have a placebo group (which may be just nicotine and no CBD). This is all do-able. They will present this plan to FDA, and if they don't hear from them in 30 days, then they are free to start the study.
IMO, CVSI will conduct the Phase 1 study (not too expensive) and if they have a positive result, they will either partner with big pharma or sell off the drug, which will be valuable.
Vandy keeps asking, "where's the drug? Where's the trials? Well, most brilliant one, that takes time and serious effort. I believe they're doing that. And I'm tired of people ignorant of the process spouting off with BKK-like incorrect maxims.
If creating a drug was easy and cheap, plenty would be doing it. I trust that Dowling and Co. are going about this as quickly as possible. Since there are studies of the successful use of CBD in animal models of nicotine addiction and opiate addiction, it's a good bet that it may work in human. The trick will be the right dose. You try to extrapolate from animal models (i.e., the concentration of CBD/nicotine in animals for a given dose) and intelligently pick two doses for the trial. Not done lightly.
If they are successful, the drug will be way more valuable than even the fantastic non-pharma side, even if sales get to $25M per quarter, which Dowling mentioned he is targeting company wide.
Hang in there and investors will be rewarded. Don't be deterred by imposters, who post repetitive drivel, often peppered with factual information. Vandy doesn't make all of his stuff up, but he can't see the forest for the trees.
I have sold 5% of my holding over 3 years to pay for college tuition and taxes, and I'm waiting a good while longer. I think this stock is an easy double this year, likely higher.
Finally, did you hear Dowling say that he didn't want to give guidance because it would be rocky up. He did not suggest he was worried about bad quarters but rather he couldn't intelligently guestimate HOW HIGH we would go.
A nice problem.
All the best.
MT
Recent CVSI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:54:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 01:28:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 01:10:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 02:36:49 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM